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FURTHER OBSERVATIONS ON AMINOPTERIN FOR PSORIASIS*
REES B. REES, M.D. AND JAMES H. BENNETT, M.D.
Aminopterin (4-amino-pteroylglutamic acid)
is not to be recommended lightly for the treat-
ment of psoriasis, and indeed there are those who
feel it should not be used at all (1). On the other
hand, psoriasis may be disabling and life-ruining.
There are perhaps 4 million individuals in this
country who suffer with this disorder. The bene-
fits of the drug are brought about by its toxic
effect, and about one-fifth of individuals who
take it according to schedules used by us do have
disagreeable symptoms such as: aphthous
stomatitis, gastrointestinal distress, temporary
intensification of lesions, temporary partial hair
loss, and temporary leukopenia. In addition, we
have learned to be very cautious in using aminop-
term in the following situations: universal
erythroderma (due to psoriasis), involvement of
stasis dermatitis with psoriasis, intertriginous
psoriasis, and in small, frail, aged or debilitated
individuals. Last but not least, the drug must
never be given during pregnancy as it is an
abortifacient and might induce fetal malforma-
tions (2). Indeed there is serious question as to
whether it should ever be given to a woman of
childbearing age.
RATIONALE
The rationale for its use is as follows: psoriasis
appears to be an hereditary tendency (3, 4) for
excessive epithelial activity, usually in localized
sites, leading to overproduction of horny cells
which tend to accumulate.
To Gubner (5) must go the credit for first point-
ing out that aminopterin may be beneficial in
psoriasis, and that its epithelial-inhibiting effect
may be more pronounced than its suppressive
action on blood forming organs. Others besides
ourselves have confirmed Gubner's observations
(6, 7). We were able to confirm the epithelial-
suppressing effect by demonstration of a marked
cytotoxic action on monkey kidney epithelium in
tissue culture (8).
Aminopterin interferes with folic acid mctabo-
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lism. More specifically, it interferes with con-
version of folic acid to citrovorum factor, which is
its biologically active form. This nonavailability
of the citrovorum factor interferes with the bio-
synthesis of purincs and pyrimidines, which are
important structural components of nucleic acids,
the interconversion of glyeinc and serine, and
transmcthylation reactions (9).
The action, then, of aminopterin is to regulate
the too-rapid epithelial cell reproduction in
psoriasis, bringing about a replacement of psori-
atic plaques by normal skin. Normal epithelial
growth is unaltered because suppression usually
requires a dosage of aminopterin in excess of that
used for the treatment of psoriasis.
DOSAGE SCHEDULES
We have attempted to find safe, effective
dosage schedules. The range between benefit and
toxicity is narrow. Aminopterin is marketed in
0.5 mg. tablets for oral use. It should not be
prescribed, but must be given directly to the
patient, with explicit instructions as to use. It is
our custom to give the patient no more than 12 of
the 0.5 mg. tablets at one time. Five dosage
schedules have been used, as follows:
I. one 0.5 mg. tablet by mouth daily for 6
days.
as in I, but repeated after one week.
one daily for 12 days.
two daily for 6 days.
two daily for 3 days. Then one daily for
6 days.
These courses may be repeated from time to time
as indicated, with suitable intervening rest
periods. The patient is cautioned to discontinue
the treatment at once if any untoward effect
whatsoever occurs. Blood counts arc performed
frequently.
RESULTS
In 1955, we reported results of treatment of 171
psoriatic patients with aminopterin (8), the
majority taking the drug according to schedules
II, III, or IV. Approximately 42% experienced
clearing of their lesions, although there was a
distressing tendency for the lesions to reappear
II.
III.
IV.
V.
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Schedule
I
II
III
IV
V
Total
T
e5:
23
50
175
35
46
329
Response
75—100% 50—75% 0—50%
13 6 4
25 16 9
99 38 38
19 8 8
30 13 3
186 81 62
TABLE II
Frequency of Courses
One course
Every 3 weeks
Monthly
6 weeks—2 months
2—4 times a year
Once yearly
Once every 3 years... .
44 (13 with no benefit)
68
77
55
72
12
1
329
TABLE JR
Over-All Toxic Effects
Schedule I II III IV V
Total reactions
Total patients with
reactions
within a short time (1—2 weeks in most instances).
About 14% of them had toxic effects, mostly of a
transitory and mild nature.
An additional 42% noted some improvement,
leaving only 16% (approximately) who had no
benefit.
For the purpose of the present study, the
records of the original 171 patients were reviewed
and brought up to date as of April, 1958. By this
time, many of the original patients had been
retreated, using the same or more vigorous
dosage schedules. Moreover, data on 158 addi-
tional patients had become available, bringing
the total to 329.
As shown in Table I, approximately 57% of
these patients noted 75—100% response and
another 25% had 50—75% improvement. About
18% had insufficient benefit to warrant re-use of
this potentially dangerous drug.
Frequency of Courses. It was necessary to
repeat the course of treatment, as shown in
Table II. Only one course was given to 44 pa-
tients, 31 of whom had lasting benefit.
Toxic Effects. As shown in Table III, toxic
effects occurred in 70 of 329 patients, an over-all
incidence of 21%. Roughly speaking then, one
patient in five may be expected to have one or
more toxic effects.
Under "Miscellaneous Reactions" there was
one patient with recurrent mastitis and another
with bleeding from the kidney. The latter oc-
curred in a 52 year old man on each of two oc-
casions after taking one 0.5 mg. tablet daily for
12 days. The episodes of hematuria commenced
on the 12th day after completion of the course of
treatment and lasted several days on each
occasion. According to the urologist, the renal
calyx was the source of bleeding.
There were four instances of leukopenia (WBC
below 5000/cu.mm. ranging between 2300 and
4300 WBC/cu.mm.). In three of these patients
the WBC had returned to normal by the time the
count was repeated. The fourth patient had
2 lcukopenia persisting for 3 months at the time of
this report. His hematologist attributes this to
hypersplenism and not aminopterin. The bone
0 marrow was normal. Two of these four patients
0 had taken only 6 mg. of aminopterin. There
were no instances of anemia. Although hundreds
10
of bloodcounts have been performed, we consider
q the data here to be incomplete because practi-t cally all of our patients were treated on an
ambulatory basis, and a leukocyte depression
may have been missed in many instances.
One patient had an episode of "heat stroke"
within three weeks after taking a course of
aminopterin (Schedule III). He had extensive
psoriasis and was working in the sun during hot
weather. He has subscci uently taken aminoptcrin
TABLE I
Results of Aminopterin Treatment of 329 Psoriasis
Patients
Patients Treated
Aphtbous lesions
Intensification or ero-
sions of the lesions..
Transient partial
alopecia
Gastrointestinal symp-
toms
Leukopenia
Miscellaneous
23
0
1
0
0
0
2
2
50
2
2
0
1
0
1
6
6
175
27
9
4
4
2
1
47
42
35
9
4
3
2
2
0
20
11
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without difficulty. It seems likely that this
episode was due to extensive anhidrosis (10).
A generalized scarlatiniform rash occurred in a
40 year old woman after she took one 0.5 mg.
tablet. However, she was taking other medica-
tions, including reserpine, at the time. If the rash
were due to aminopterin, it would be the only
instance of idiosyncrasy, as opposed to direct
toxic effect, that we have encountered.
Two patients suffered bowel obstructions
within a few weeks of taking aminoptcrin, re-
quiring surgical intervention. One patient has
taken repeated courses of aminopterin subse-
quently without trouble. One patient had a
strangulated hernia which may have been coinci-
dental, because of a time lag in relationship to
taking the drug.
The most alarming complications encountered
were reported in a previous study, and consisted
of a combination of leukopenia, fever, epithclial
sloughs and temporary hair loss (8). We have not
seen more instances of reactions this severe,
probably because of our greater familiarity with
limitations of the drug.
It would now appear to be unnecessary to rely
upon administration of citrovorum factor for
reactions to aminopterin, as discussed in a pre-
vious report. Rather, it is important to initiate
treatment with a conservative schedule, and also
to discontinue treatment promptly whenever
there is the slightest hint of a toxic reaction, The
citrovorum factor ("Lcucovorin") is available in
1 cc. ampules containing 3 mg. for intramuscular
use. In case of a severe toxic reaction it may be
given daily until remission is achieved.
Long Term Results
In this group of 41 patients 28 experienced 75—
100% clearing of lesions, 12 had 50—75% benefit,
and one had only 25—50% benefit (Table IV).
Obviously, this was a highly selected group in the
sense that they would not have continued to take
repeated courses for months and years if the
treatment had not been worthwhile.
Eighteen of them were men and 23 were
women; the average duration of the disease was
21 years; prior treatment had included "every-
thing" and they had concluded, in the word of
one patient, that the situation was "hopeless".
Toxicity—Long Term Group
These patients were treated over a period of
one to five years. All of these Q3patients were
(7
TABLE IV
Long Term Results (41 Patients)
Total dose: 100 mg. (200 tablets) or more.
Average dose: 197 mg. (maximum 348 mg.)
Schedule I II III IV V
Number of Patients 1 2 20 5 13
Frequency of Repetition of Courses
3 week interval 8 patients
monthly interval 20 patients
6 week—2 month interval 10 patients
2—4 times per year interval 3 patients
TABLE V
Toxicity—Long Term Group (41 patients)
16 patients—39%
Sore mouth
Intensification
Gastrointestinal symptoms
Hair loss
Leukopenia
TABLE VI
Analysis of Data of Patients Having 75—100%
Response
I. 186 out of 329 cases
II. 57% of those treated
III. Schedules I II
Cases 13 25
Reaction 2 1
III
99
33
IV
19
9
V
30
7
Total
186
52
IV. 28% had toxic reactions
able to resume treatment despite these temporary
ill effects (Table V).
Patients Having 75—100% Response
It is evident from Table VI that patients
having an excellent response are more likely to
have concomitant temporary toxic effects than
those having less than a 75—100% response. It is
also evident' that one need not necessarily take
the medication according to the most vigorous
schedule (V and IV) in order to have such a
response. Such figures naturally would have to be
corrected for such factors as the weight of the
patient and the type of involvement; but in
general, the need for varying the dosage schedule
according to the response of the lesions and the
tolerance of the patient is borne out by these
figures. It will be seen also that administration of
10
2
2
1
1
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Schedule IV was accompanied by aa almost
prohibitively high incidence of reactions (47%).
Drug Resistance
The question of whether an individual may
obtain a satisfactory temporary response to the
administration of aminopterin, and then fail to
respond to readministration cannot be answered
clearly. Some 19 individuals appeared to have
developed resistance, 14 of these having had
75—100% benefit originally, and 5 of them 50—
75% benefit. Twelve of them failed to respond
subsequently even though they took the drug
according to two or three of the more vigorous
schedules (III, V and IV). The other seven pa-
tients in this "resistant" group appeared to
respond well to administration subsequently of a
more vigorous treatment schedule.
Enduring Benefit with Small Doses
Thirty-one patients enjoyed remissions of a
year or more after taking a single course of
aminopterin. In other words, about 9% of the
entire group of patients derived lasting benefit
from 6 mg. or less. It must be admitted that one
might reasonably expect spontaneous remissions
in this small a percentage of a group of psoriatic
patients. Osborne, for example, points out that
as many as 20-30% may experience spontaneous
clearing of their lesions in a 6 to 12 month
period (11). On the other hand, the average
duration of the disease in this group was eight
years, ranging from six months to 30 years, and
the disease had not yielded to conventional
therapy.
Other Antimetabolites
Daraprim (2, 4-diamino-5-p-chloropteroyh6
ethyl-pyrimidine), which is a potent folic acid
antagonist, and which has a suppressive effect on
erythrocytes, was given to 12 psoriatic patients
in a dosage of 25 mg. daily for one month, without
benefit or significant ill-effect. Similar lack of
response was noted with purinethol (6 mercapto
purine), a synthetic analogue of adenine (a
nucleic acid constituent) and of the purine base
hypoxanthine. This drug is purported to interfere
with nucleic acid biosynthesis. It was admin-
istered orally to 12 patients in a dose of 50 mg.
four times daily for six days.
DIscussIoN
The approach to management as outlined in
this study obviously is not the answer to the
psoriasis problem. However, it does focus atten-
tion upon a possible approach in research. The
thesis upon which much effort has been expended
in the past, namely, that psoriasis is based upon
faulty fat metabolism and pancreatic insuf-
ficiency, has (in our opinion) at long last been
laid to rest (12, 13).
We feel that the present study may encourage
further investigation into the metabolism of the
epithelial cell itself, with the thought that there
might be some inherent metabolic defect or fault
in epithelial cell reproduction in psoriasis. Recent
work has shown a localized defect in protein
metabolism in the psoriatic lesion, presumably
due to lack of dipeptidase activity, resulting in a
lowered content of water-binding free amino
nitrogen and elevated sulfhydryl content in the
scale. Some investigators feel that the dipepti-
dases are inhibited by a substance, not yet
defined, in the scale (14). Others feel that instead
of an inhibitor, there is lack of an enzyme
activator (15). In any event, the non-functioning
dipeptidases are present, as has been shown by
stimulating their activity with cobalt (16). One
may speculate as to whether there is a specific
defect in protein metabolism in psoriasis, or
whether the abnormalities in protein metabolism
are the result of the greatly accelerated growth of
epithelial cells in this disease. Suffice it to say,
for the purposes of this report, that aminopterin
undoubtedly exerts its benefit in psoriasis be-
cause of its antianabolic activity.
The practicality of this approach is limited by
the dangerous potentiality of aminopterin, and
by certain absolute contraindications. However,
in the words of one authority, there are only two
internal medications which may fairly regularly
benefit psoriasis, these being inorganic arsenic
and aminopterin (17). To these may possibly be
added some newer corticosteroids, such as
triamcinolone and methylprednisolone, but of
course the use of these compounds is not without
hazard also.
SUMMARY AND CONcLUSIoNs
The 1955 report on the use of aminopterin in
treatment of psoriasis is augmented and certain
clinical aspects are inquired into in more detail.
The theme of this study, as before, is an attempt
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to show that conservative dosages of aminopterin
may clear or improve lesions of psoriasis without
incurring too high an incidence of toxic effects.
Aminopterin was administered to 329 individuals
with psoriasis according to schedules used in a
previous study. Approximately 57% of these
patients noted 75—100% clearing of their lesions,
and another 25%, approximately, had 50—75%
clearing. This makes a total of 82% having
enough benefit to make the treatment seem
worthwhile. The over-all incidence of toxicity was
found to be about 21%, although patients having
an excellent response had an incidence of re-
actions of about 28%. This substantiates the view
that benefit is brought about largely by toxic
effect. A special group of 41 patients was singled
out for study of longterm effects of aminopterin
given in repeated courses. Each of these patients
took in excess of 100 mg. of aminopterin during a
time period of one to five years. While the inci-
dence of toxic effects was over 39%, these were
mild, and did not interfere with readministration
of the drug.
Other points touched upon in this study include
a discussion of potentially serious reactions,
analysis of data in patients having 75—100%
response, inquiry into the question of drug re-
sistance, presentation of data regarding enduring
benefit with small doses in some of the more
fortunate patients, and the lack of response of
psoriasis to two other antimetabolites.
Controls in this study were provided as follows:
1. All of the patients had treatment-resistant
psoriasis, so far as conventional methods are
concerned.
2. The results of treatment with various
dosage schedules of aminopterin are compared.
3. A comparison of the results with two other
antimetabolites, both of which failed to bring
about any benefit in a group of 12 patients each,
thereby providing a baseline.
As in a previous report, no attempt is made to
urge trial of this approach in the treatment of
psoriasis other than on a well controlled investi-
gative basis.
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DISCUSSION
DR. HARVEY BLANK (Miami, Florida): A
patient in our institution with psoriasis and
leukemia was treated with Myleran with spec-
taeular clearing of the psoriasis. Myleran® (busul-
fan) is less toxic than aminopterin. It is given in
doses of two two-milligram tablets (4 mg.) a
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half hour before breakfast every day, for four to
six weeks before deciding whether the drug has
an effect or not. Weekly white and platelet
counts are essential. Our results are not as
dramatic as those to aminopterin. Perhaps a
third responded and another third improved up
to a certain point and the other third not at all.
It is a safer drug but still only an interesting
experimental tool. I want to ask Dr. Bennett if
he has had any experience with this particular
agent?
Da. CLARENCE S. LIvINGooD (Detroit, Michi-
gan): I would like to ask Dr. Bennett about the
concentration of the aminopterin which was used
in the tissue culture toxicity studies. Dr. Funan
Hu and others in our Department have worked in
this field for many years and the minimum toxic
concentrations in tissue culture studies of a
great many drugs have been determined and
correlated with clinical results. I don't believe
that this is a particularly good method of deter-
mining the toxicity of a drug and I would tend
to disregard these results for aminopterin in
attempting to estimate its toxicity.
DR. EUGENE J. VAN SCOTT (Bethesda, Md.):
Did any other hemologic changes occur in these
patients, such as depression of the number of
platelets or retieulocytes?
In any consideration of casual therapeutic use
of metabolic antagonists in psoriasis perhaps we
should keep in mind possible mutagenic effects of
these drugs.
DR. JAMES H. BENNETT (in closing): I was
quite interested in Doctor Blank's remarks. We
are glad to see that other antimetabolites are
being tried. We have had no personal experience
with Myeleran.
In answer to Doctor Livingood's question, the
dilution we used was 0.1 mg. of aminopterin per
ml. of liquid nutrient medium. This work was
reported in our previous paper (flees, R. B.;
Bennett, J. H.; and Bostick, W. L.: Aminopterin
for Psoriasis, A.M.A. Arch. Dermat. 72: 133
(Aug.) 1955).
In answer to Doctor Van Scott's question, the
platelet counts were done only occasionally when
there had been a severe reaction or when a
leukopenia was present. Routinely we checked
just the normal complete blood count.
In answer to the question of aminopterin
possibly inducing leukemia, we have no informa-
tion on this subject.
